Medical School

  • Brown University , 2007 , Providence , RI


  • Boston Combined Residency Program (BCRP) , 2010 , Boston , MA


Pediatric Hematology-Oncology
  • Boston Children's Hospital/Dana-Farber Cancer Institute , 2014 , Boston , MA


Dr. Stacy Croteau is a pediatric hematologist and clinical researcher at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, where she specializes in bleeding and clotting disorders. She completed her undergraduate and medical education at Brown University and then pursued training in Pediatrics and Pediatric Hematology/Oncology at Boston Children's Hospital and Dana-Farber Cancer Institute. Dr. Croteau joined the Boston Hemophilia Center as the associate director in 2014 and became the medical director in 2019. She enjoys clinical care of pediatric patients and leading research efforts to push the frontier of the quality and innovation in our current standards of medical practice.

Dr. Croteau currently serves at the primary investigator for several industry-sponsored and investigator initiated clinical trials and as the national chair of the American Thrombosis Hemostasis Network (ATHN)/National Hemophilia Program Coordinating Center (NHPCC) Transition Working Group. She also serves on the American Society of Hematology's Scientific Committee for Hemostasis. Her primary areas of academic interest are early drug development, advancing an approach for rationally designed personalized-prophylaxis regimens in hemophilia, and quality improvement efforts targeting patient transition from pediatric to adult care.


  • American Board of Pediatrics, General Pediatrics
  • American Board of Pediatrics, Pediatric Hematology and Oncology


Publications powered by Harvard Catalyst Profiles

  1. Symptomatic Pulmonary Embolus after Catheter Removal in Children with Catheter Related Thrombosis: A Report from the CHAT Consortium. J Thromb Haemost. 2021 Oct 08. View abstract
  2. A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children's Hospital-Acquired Thrombosis Consortium. Pediatr Crit Care Med. 2021 Aug 18. View abstract
  3. Phage display broadly identifies inhibitor-reactive regions in von Willebrand factor. J Thromb Haemost. 2021 Jul 13. View abstract
  4. The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B. Haemophilia. 2021 Sep; 27(5):802-813. View abstract
  5. Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency. J Thromb Haemost. 2021 04; 19(4):976-982. View abstract
  6. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. J Manag Care Spec Pharm. 2021 Mar; 27(3):316-326. View abstract
  7. Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27(2):211-220. View abstract
  8. Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural). Haemophilia. 2021 Jan; 27(1):49-59. View abstract
  9. Discussing investigational AAV gene therapy with hemophilia patients: A guide. Blood Rev. 2021 05; 47:100759. View abstract
  10. 2021 clinical trials update: Innovations in hemophilia therapy. Am J Hematol. 2021 01; 96(1):128-144. View abstract
  11. Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium. J Pediatr. 2021 01; 228:252-259.e1. View abstract
  12. Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study. Haemophilia. 2021 Mar; 27(2):e270-e273. View abstract
  13. The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. Am J Hematol. 2020 08; 95(8):960-965. View abstract
  14. Low von Willebrand factor in pediatric patients: Retrospective analysis of 293 cases informs diagnostic and therapeutic decision making. Pediatr Blood Cancer. 2020 09; 67(9):e28497. View abstract
  15. Utility of Blood Cultures and Empiric Antibiotics in Febrile Pediatric Hemophilia Patients With Central Venous Access Devices. Pediatr Emerg Care. 2020 Apr 28. View abstract
  16. Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres. Haemophilia. 2020 May; 26(3):e128-e129. View abstract
  17. An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation. J Inherit Metab Dis. 2020 07; 43(4):880-890. View abstract
  18. Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. Res Pract Thromb Haemost. 2020 Feb; 4(2):326-333. View abstract
  19. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clin Pharmacokinet. 2020 02; 59(2):245-256. View abstract
  20. Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a survey of US patients with haemophilia and obesity (PwHO) and their partners and caregivers. Haemophilia. 2020 Jan; 26 Suppl 1:3-19. View abstract
  21. Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream. Blood Adv. 2019 12 23; 3(24):4166-4176. View abstract
  22. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users. Haemophilia. 2020 Jan; 26(1):56-63. View abstract
  23. Neuropsychological function in children with hemophilia: A review of the Hemophilia Growth and Development Study and introduction of the current eTHINK study. Pediatr Blood Cancer. 2020 01; 67(1):e28004. View abstract
  24. Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). J Blood Med. 2019; 10:335-340. View abstract
  25. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia. 2019 Jul; 25(4):668-675. View abstract
  26. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia. 2019 03; 25(2):e126-e129. View abstract
  27. Shifting Landscape of Hemophilia Therapy: Implications for Current Clinical Laboratory Coagulation Assays. Am J Hematol. 2018 Jun 08. View abstract
  28. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. J Thromb Haemost. 2018 07; 16(7):1437-1441. View abstract
  29. Evolving Complexity in Hemophilia Management. Pediatr Clin North Am. 2018 06; 65(3):407-425. View abstract
  30. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 Jul; 2(3):607-614. View abstract
  31. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Res Pract Thromb Haemost. 2018 Jul; 2(3):535-548. View abstract
  32. Fifth Åland Island conference on von Willebrand disease. Haemophilia. 2018 May; 24 Suppl 4:5-19. View abstract
  33. The spectrum of bleeding in women and girls with haemophilia B. Haemophilia. 2018 Mar; 24(2):180-185. View abstract
  34. Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism. Front Pediatr. 2017; 5:68. View abstract
  35. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor. Haemophilia. 2017 Mar; 23(2):e93-e98. View abstract
  36. 2017 Clinical trials update: Innovations in hemophilia therapy. Am J Hematol. 2016 12; 91(12):1252-1260. View abstract
  37. The clinical spectrum of kaposiform hemangioendothelioma and tufted angioma. Semin Cutan Med Surg. 2016 Sep; 35(3):147-52. View abstract
  38. Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. Pediatr Blood Cancer. 2016 10; 63(10):1822-8. View abstract
  39. Center-Based Quality Initiative Targets Youth Preparedness for Medical Independence: HEMO-Milestones Tool in a Comprehensive Hemophilia Clinic Setting. Pediatr Blood Cancer. 2016 Mar; 63(3):499-503. View abstract
  40. Author's response: 'Transition considerations for extended half-life factor products'. Haemophilia. 2015 Sep; 21(5):e454-5. View abstract
  41. Transition considerations for extended half-life factor products. Haemophilia. 2015 May; 21(3):285-8. View abstract
  42. Use of a fever fast track tool to reduce time to antibiotic dose in febrile pediatric oncology patients. J Clin Oncol. 2014 Oct 20; 32(30_suppl):222. View abstract
  43. Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centre-based pharmacy hit the mark? Haemophilia. 2015 Mar; 21(2):190-5. View abstract
  44. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly. J Pediatr. 2014 Feb; 164(2):383-8. View abstract
  45. Novel dominant ß-thalassemia: Hb Boston-Kuwait [codon 139/140(+T)]. Pediatr Blood Cancer. 2013 Oct; 60(10):E131-4. View abstract
  46. Resolving bony abnormality evolves to diffuse large B-cell lymphoma. Pediatr Blood Cancer. 2013 Oct; 60(10):E113-5. View abstract
  47. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr. 2013 Jan; 162(1):142-7. View abstract
  48. Temporal and spatial expression of bone morphogenetic protein-2, -4, and -7 during distraction osteogenesis in rabbits. Bone. 2000 Sep; 27(3):453-9. View abstract
  49. Bone morphogenetic proteins in orthopedics: from basic science to clinical practice. Orthopedics. 1999 Jul; 22(7):686-95; quiz 696-7. View abstract